Immunocore Holdings plc Income Tax Expense Continuing Operations
Immunocore Holdings plc (IMCR) reported Income Tax Expense Continuing Operations of GBP 151.00 thousand for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Expense Statement › Income Tax
ifrs-full:IncomeTaxExpenseContinuingOperations · last filed 2023-08-10
- Immunocore Holdings plc income tax expense continuing operations for the quarter ending 2023-06-30 was 151.00K GBP.
- Immunocore Holdings plc income tax expense continuing operations for the quarter ending 2022-12-31 was 2.13M GBP, a 894.86% increase year-over-year.
- Immunocore Holdings plc income tax expense continuing operations for the quarter ending 2022-09-30 was -1.24M GBP.
- Immunocore Holdings plc income tax expense continuing operations for the quarter ending 2022-06-30 was -2.15M GBP.
| Period end | Income Tax Expense Continuing Operations 3 month | Income Tax Expense Continuing Operations 6 month | Income Tax Expense Continuing Operations 9 month | Income Tax Expense Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-06-30 | 151.00K GBP 6-K · filed 2023-08-10 | 387.00K GBP 6-K · filed 2023-08-10 | ||
| 2022-12-31 | 2.13M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 885.00K GBP derived: sum of 2 quarters · filed 2023-03-01 | -1.27M GBP derived: sum of 3 quarters · filed 2023-08-10 | -2.92M GBP 20-F · filed 2023-03-01 |
| 2022-09-30 | -1.24M GBP 6-K/A · filed 2022-11-18 | -3.40M GBP derived: sum of 2 quarters · filed 2023-08-10 | -5.05M GBP 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | -2.15M GBP 6-K · filed 2023-08-10 | -3.81M GBP 6-K · filed 2023-08-10 | ||
| 2021-12-31 | 214.00K GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -1.91M GBP derived: sum of 2 quarters · filed 2023-03-01 | -9.40M GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | -2.13M GBP 6-K/A · filed 2022-11-18 | -9.62M GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | -13.27M GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | -22.26M GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | -16.55M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |